Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378102 · ClinicalTrials.gov registry record · Early Phase 1
Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation
A Early Phase 1 study of Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Mari Dallas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03378102 is a Early Phase 1 study of Allogeneic Hematopoietic Stem Cell Transplantation that is actively recruiting participants, run by Mari Dallas. The registered enrollment target is 20 participants, below the 113-participant average among 3 other Allogeneic Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03378102, a Early Phase 1 study of Allogeneic Hematopoietic Stem Cell Transplantation, is actively recruiting participants, sponsored by Mari Dallas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxicities of adoptive T cell therapy. Adoptive T cell therapy is an investigational (experimental) therapy that works by using the blood of a donor that has immunity against the virus. The donor cells are collected and then the cells, called T cells, that are capable of defending against the virus are selected out. These selected T cells are then infused back into the patient, to try to give the immune system the ability to fight the infection. Adoptive T cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Conditions Studied
Interventions
- BIOLOGICAL IFN-gamma-secreting HAdV antigen specific T cells
Study Locations (1)
Ohio
- University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03378102
The ClinicalTrials.gov registry entry for NCT03378102 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 3 other Allogeneic Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (82% lower). The listed sponsor is Mari Dallas, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which IFN-gamma-secreting HAdV antigen specific T cells is the first listed.
NCT03378102 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03378102 about?
NCT03378102 is a clinical study titled "Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation". The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxic...
What is the current status of trial NCT03378102?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-01-04. Estimated completion is 2028-12.
What conditions does trial NCT03378102 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Stem Cell Transplantation.
What interventions are being tested in trial NCT03378102?
The interventions under investigation include: IFN-gamma-secreting HAdV antigen specific T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03378102?
This trial is sponsored by Mari Dallas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03378102 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Nutrition OUtReach In Systems of Healthcare
RECRUITING · NA
-
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.